Overview

Mechanisms of Diuretic Resistance in Heart Failure

Status:
Not yet recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
This study will employ a randomized order, double-blind, repeated measures dose ranging design. This design was chosen in order to generate multiple within-subject serial loop diuretic dose response exposures. The overall study schema will include 50 diuretic resistant HF patients and 25 diuretic responsive heart failure (HF) patients.
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Treatments:
Bumetanide